Literature DB >> 10933372

Ventricular tachycardias above the initially programmed tachycardia detection interval in patients with implantable cardioverter-defibrillators: incidence, prediction and significance.

D Bänsch1, M Castrucci, D Böcker, G Breithardt, M Block.   

Abstract

OBJECTIVES: This retrospective study was performed to provide data on ventricular tachycardias (VT) with a cycle length longer than the initially programmed tachycardia detection interval (TDI) in patients with implantable cardioverter defibrillators (ICDs).
BACKGROUND: It has been clinical practice to program a safety margin of 30 to 60 ms between the slowest spontaneous or inducible VT and the TDI.
METHODS: Baseline characteristics of 659 consecutive patients with ICDs were prospectively; follow-up information was retrospectively collected.
RESULTS: During a mean follow-up of 31+/-23 months, 377 patients (57.2%) had at least one recurrent VT or ventricular fibrillation; 47 patients (7.1%) suffered 61 VTs above the TDI. The risk of a VT above the TDI ranged between 2.7% and 3.5% per year during the first four years after ICD implantation. The difference between the cycle length of the slowest VT before ICD implantation, spontaneous or induced, and the first VT above TDI was 108+/-58 ms. Fifty-four VTs (88.5%) above the TDI were associated with significant clinical symptoms (angina or palpitation 63.9%, heart failure 6.6% and syncope 8.2%). Six patients (9.8%) had to be resuscitated. Kaplan-Meyer analysis identified New York Heart Association class II or III (p = 0.021), ejection fraction < 0.40 (p = 0.027), spontaneous (p<0.001) or inducible (p<0.001) monomorphic VTs and the use of class III antiarrhythmic drugs (amiodarone, p<0.001; sotalol, p = 0.004) as risk predictors of VTs above the TDI. The risk of recurrent VTs above TDI was 11.8%, 12.5% and 26.6% during the first, second and third year after first VT above TDI, respectively.
CONCLUSIONS: The risk of VTs above the TDI is significantly increased in some patients, and many VTs above TDI cause significant clinical symptoms. A larger safety margin between spontaneous or inducible VTs and the TDI seems to be necessary in selected patients. This is in conflict with an increased risk of inadequate episodes and demands highly specific and sensitive detection algorithms in these patients.

Entities:  

Mesh:

Year:  2000        PMID: 10933372     DOI: 10.1016/s0735-1097(00)00733-6

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  8 in total

1.  Case report: Delayed detection of ventricular tachycardia due to intradevice interactions by implantable atrio-ventricular pacer/cardioverter defibrillator.

Authors:  Bharat K Kantharia; Farooq A Padder
Journal:  J Interv Card Electrophysiol       Date:  2006-10-03       Impact factor: 1.900

2.  Cardiac implantable electrical devices: bioethics and management issues near the end of life.

Authors:  Freddy M Abi-Samra
Journal:  Ochsner J       Date:  2011

3.  VT ablation in heart failure.

Authors:  D Bänsch; R Schneider; I Akin; C A Nienaber
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2012-03-14

Review 4.  Algorithms for better arrhythmia discrimination in implantable cardioverter defibrillators.

Authors:  R Schimpf; C Wolpert; B Lüderitz
Journal:  Curr Cardiol Rep       Date:  2001-11       Impact factor: 2.931

5.  Ventricular tachycardia inducibility after radiofrequency ablation affects the outcomes in patients with coronary artery disease and implantable cardioverter-defibrillators: The role of left ventricular function.

Authors:  Andrea Colella; Marzia Giaccardi; Raffaele Molino Lova; Carmine Liccardi; Gian Franco Gensini
Journal:  J Interv Card Electrophysiol       Date:  2009-01-16       Impact factor: 1.900

Review 6.  Optimal tachycardia programming in ICDs : Recommendations in the post-MADIT-RIT era.

Authors:  Carsten W Israel; Tatsiana Burmistrava
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2016-09

7.  Single-chamber ICD, single-zone therapy in primary and secondary prevention patients: the simpler the better?

Authors:  S González-Enríquez; F Rodríguez-Entem; V Expósito; C Castrillo-Bustamante; A Canteli; A Solloso; I Madrazo; J J Olalla
Journal:  J Interv Card Electrophysiol       Date:  2012-10-19       Impact factor: 1.900

8.  A trial design for evaluation of empiric programming of implantable cardioverter defibrillators to improve patient management.

Authors:  John M Morgan; Laurence D Sterns; Jodi L Hanson; Kevin T Ousdigian; Mary F Otterness; Bruce L Wilkoff
Journal:  Curr Control Trials Cardiovasc Med       Date:  2004-11-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.